Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer.
In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen -specific immunization and its relationship with the systemic administration of IL-2.
HoubiersJ.G., van der BurgS.H., van de WateringL.M., TollenaarR.A., BrandA., van de VeldeC.J., MeliefC.J.: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer, 72: 637–641, 1995.
5.
RosenbergS.A.: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst, 88: 1635–1644, 1996.
6.
ClementeC.G., MihmM.C.Jr., BufalinoR., ZurridaS., ColliniP., CascinelliN.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77: 1303–1310, 1996.
7.
von Mensdorff-PouillyS., VerstraetenA.A., KenemansP., SnijdewintF.G., KokA., Van KampG.J., PaulM.A., Van DiestP.J., MeijerS., HilgersJ.: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol, 18: 574–583, 2000.
8.
MukherjiB., ChakrabortyN.G., SivanandhamM.: T-cell clones that react against autologous human tumors. Immunol Rev, 116: 33–62, 1990.
9.
RosenbergS.A., YangJ.C., SchwartzentruberD.J., HwuP., MarincolaF.M., TopalianS.L., RestifoN.P., DudleyM.E., SchwarzS.L., SpiessP.J., WunderlichJ.R., ParkhurstM.R., KawakamiY., SeippC.A., EinhornJ.H., WhiteD.E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med, 4: 321–327, 1998.
10.
NestleF.O., AlijagicS., GillietM., SunY., GrabbeS., DummerR., BurgG., ShadendorfD.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 4: 328–332, 1998.
11.
KuglerA., StuhlerG., WaidenP., ZollerG., ZobywalskiA., BrossartP., TrefzerU., UllrichS., MullerC.A., BeckerV., GrossA.J., HemmerleinB., KanzL., MullerG.A., RingertR.H.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med, 6: 332–336, 2000.
12.
AtkinsM.B., LotzeM.T., DutcherJ.P., FisherR.I., WeissG., margolinK., AbramJ., SznolM., ParkinsonD., HawkinsM., ParadiseL., KunkelL., RosenbergS.A.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17: 2105–2116, 1999.
13.
FisherR.I., RosenbergS.A., FyfeG.: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 6(Suppl 1): 55–57, 2000.
14.
MarchandM., van BarenN., WeynantsP., BrichardV., DrenoB., TessierM.H., RankinE., ParmianiG., ArientiF., HumbletY., BourlondA., VanwijckR., LienardD., BeauduinM., DietrichP.Y., RussoV., KergerJ., MasucciG., JagerE., De GreveJ., AtwpodienJ., BrasseurF., CoulieP.G., Van Der Bruggenp, BoonT.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. Int J Cancer, 80: 219–230, 1999.
15.
HsuehE.C., NathansonL., FoshagL.J., EssnerR., NizzeJ.A., SternS.L., MortonD.L.: Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer, 85: 2160–2169, 1999.
16.
RosenbergS.A., PackardB.S., AebersoldP.M., SolomonD., TopalianS.L., ToyS.T., SimonP., LotzeM.T., YangJ.C., SeippC.A.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 319: 1676–1680, 1988.
17.
MarincolaF.M., JaffeeE.M., HicklinD.J., FerroneS.: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol, 74: 181–273, 2000.
18.
WalkerP.R., SaasP., DietrichP.Y.: Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol, 158: 4521–4524, 1997.
19.
LengauerC., KinzlerK.W., VogelsteinB.: Genetic instabilities in human cancers. Nature, 396: 643–649, 1998.
20.
PerouC.M., SorlieT., EisenM.B., Van de Rijn, JeffreyS.S., ReesC.A., PollackJ.R., RossD.T., JohnsenH., AkslenL.A., FlugeO., PergamenschikovA., WilliamsC., ZhuS.X., LonningP.E., Borresen-DaleA.L., BrownP.O., BotsteinD.: Molecular portraits of human breast tumours. Nature, 406: 747–752, 2000.
21.
LeeK.H., PanelliM.C., KimC.J.: Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol, 161: 4183–4194, 1998.
22.
JagerE., RinghofferM., AltmannsbergerM.: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer, 71: 142–147, 1997.
23.
OhnmachtG.A., WangE., MocellinS.: Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol, 167: 1809–1820, 2001.
24.
FerroneS., MarincolaF.M.: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today, 16: 487–494, 1995.
25.
CormierJ.N., HijaziY.M., AbatiA.: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer, 75: 517–524, 1998.
26.
ScheibenbogenC., WeyersI., RuiterD., WillhauckM., BittingerA., KeilholzU.: Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol, 19: 375–380, 1996.
27.
RikerA., CormierJ., PanelliM.: Immune selection after antigen-specific immunotherapy of melanoma. Surgery, 26: 112–120, 1999.
28.
AnichiniA., MollaA., MortariniR.: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med, 190: 651–667, 1999.
29.
PageM.J., AmessB., TownsendR.R.: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA, 96: 12589–12594, 1999.
30.
WangE., MarincolaF.M.: A natural history of melanoma: serial gene expression analysis. Immunol Today, 21: 619–623, 2000.
31.
YeeC., RiddellS.R., GreenbergP.D.: In vivo tracking of tumor-specific T cells. Curr Opin Immunol, 13: 141–146, 2001.
32.
BrownP.O., BotsteinD.: Exploring the new world of the genome with DNA microarrays. Nat Genet, 21: 33–37, 1999.
33.
PaweletzC.P., CharboneauL., BichselV.E.: Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene, 20: 1981–1989, 2001.
WolfelT., KlehmannE., MullerC., SchuttK.H., Meyer zum BuschenfeldeK.H., KnuthA.: Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med, 170: 797–810, 1989.
36.
PockajB.A., SherryR.M., WeiJ.P.: Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer, 73: 1731–1737, 1994.
37.
SallustoF., LenigD., ForsterR., LippM., LanzavecchiaA.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401: 708–712, 1999.
38.
PanelliM.C., BettinottiM.P., LallyK.: A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol, 164: 4382–4392, 2000.
39.
ThurnerB., HaendleI., RoderC.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med, 190: 1669–1678, 1999.
40.
JagerE., MaeurerM., HohnH.: Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma- associated peptides. Int J Cancer, 86: 538–547, 2000.
41.
PanelliM.C., RikerA., KammulaU.: Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol, 164: 495–504, 2000.
42.
KammulaU.S., LeeK.H., RikerA.I.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol, 163: 6867–6875, 1999.
43.
ParkinsonD.R., AbramsJ.S., WiernikP.H.: Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol, 8: 1650–1656, 1990.
44.
CoulieP.G., SomvilleM., LehmannF.: Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer, 50: 289–297, 1992.
45.
van der BruggenP., TraversariC., ChomezP.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254: 1643–1647, 1991.
46.
MarincolaF.M., RivoltiniL., SalgallerM.L., PlayerM., RosenbergS.A.: Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA- A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol, 19: 266–277, 1996.
47.
PittetM.J., ValmoriD., DunbarP.R.: High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med, 190: 705–715, 1999.
48.
D'SouzaS., RimoldiD., LienardD., LejeuneF., CerottiniJ.C., RomeroP.: Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer, 78: 699–706, 1998.
49.
LetschA., KeilholzU., SchadendorfD.: High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer, 87: 659–664, 2000.
50.
CormierJ.N., SalgallerM.L., PrevetteT.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am, 3: 37–44, 1997.
51.
PittetM.J., SpeiserD.E., LienardD.: Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res, 7: 796–803, 2001.
52.
ScheibenbogenC., SchmittelA., KeilholzU.: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother, 23: 275–281, 2000.
53.
LaforetM., FroelichN., ParissiadisA., BausingerH., PfeifferB., TongioM.M.: An intronic mutation responsible for a low level of expression of an HLA-A*24 allele. Tissue Antigens, 50: 340–346, 1997.
54.
JagerE., GnjaticS., NagataY.: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA, 97: 12198–12203, 2000.
55.
WangF., BadeE., KuniyoshiC.: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res, 5: 2756–2765, 1999.
56.
PanelliM.C., WangE., PhanG.: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol, 3: RESEARCH0035, 2002.
57.
MonsurroV., NagorsenD., WangE.: Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol, 168: 5933–5942, 2002.
58.
WangE., MillerL.D., OhnmachtG.A.: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res, 62: 3581–3586, 2002.
59.
MocellinS., OhnmachtG.A., WangE., MarincolaF.M.: Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer, 93: 236–242, 2001.
60.
TianQ., StreuliM., SaitoH., SchlossmanS.F., AndersonP.: A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell, 67: 629–639, 1991.
61.
TaupinJ.L., TianQ., KedershaN., RobertsonM., AndersonP.: The RNA-binding protein TIAR is translocated from the nucleus to the cytoplasm during Fas-mediated apoptotic cell death. Proc Natl Acad Sci USA, 92: 1629–1633, 1995.
62.
AndersonP.: TIA-1: structural and functional studies on a new class of cytolytic effector molecule. Curr Top Microbiol Immunol, 198: 131–143, 1995.
63.
MooreK.W., de Waal MalefytR., CoffmanR.L., O'GarraA.: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19: 683–765, 2001.
64.
Salazar-OnfrayF., PeterssonM., FrankssonL.: IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol, 154: 6291–6298, 1995.
65.
GiovarelliM., MusianiP., ModestiA.: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol, 155: 3112–3123, 1995.
66.
ZhengL.M., OjciusD.M., GaraudF.: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med, 184: 579–584, 1996.
67.
KunduN., BeatyT.L., JacksonM.J., FultonA.M.: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst, 88: 536–541, 1996.
68.
KaufmanH.L., RaoJ.B., IrvineK.R.: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother, 22: 489–496, 1999.
69.
HuangS., UllrichS.E., Bar-EliM.: Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res, 19: 697–703, 1999.
70.
KellyJ.M., DarcyP.K., MarkbyJ.L.: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol, 3: 83–90, 2002.
71.
AgarwalaS.S., GlaspyJ., O'DayS.J.: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol, 20: 125–133, 2002.
72.
AgarwalaS.S., SabbaghM.H.: Histamine dihydrochloride: inhibiting oxidants and synergising IL-2- mediated immune activation in the tumour microenvironment. Expert Opin Biol Ther, 1: 869–879, 2001.
73.
HellstrandK., BruneM., NarediP.: Histamine: a novel approach to cancer immunotherapy. Cancer Invest, 18: 347–355, 2000.
74.
MatzingerP.: Tolerance, danger, and the extended familyAnnu Rev Immunol, 12: 991–1045, 1994.
75.
MocellinS., WangE., MarincolaF.M.: Cytokines and immune response in the tumor microenvironment. J Immunother24: 392–407, 2001
76.
KamentskyL.A., KamentskyL.D.: Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data. Cytometry, 12: 381–387, 1991.
